European Union - English - EMA (European Medicines Agency)

glaxosmithkline trading services limited - fluticasone furoate, umeclidinium bromide, vilanterol trifenatate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - elebrato ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.

European Union - English - EMA (European Medicines Agency)

glaxosmithkline trading services - fluticasone furoate, umeclidinium bromide, vilanterol trifenatate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - trelegy ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - fluticasone furoate; vilanterol trifenatate; umeclidinium bromide - inhalation powder - 92microgram/1dose ; 22microgram/1dose ; 65microgram/1dose

European Union - English - EMA (European Medicines Agency)

glaxosmithkline trading services limited - fluticasone furoate, umeclidinium bromide, vilanterol trifenatate - pulmonary disease, chronic obstructive - drugs for obstructive airway diseases, - temybric ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist (for effects on symptom control and prevention of exacerbations see section 5.1).

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - fluticasone furoate (micronised); umeclidinium bromide (micronised) 74.2 mcg eqv to umeclidinium; vilanterol trifenatate (micronised) 40 mcg eqv to vilanterol - powder, metered - fluticasone furoate (micronised) 100 mcg; umeclidinium bromide (micronised) 74.2 mcg eqv to umeclidinium 62.5 mcg; vilanterol trifenatate (micronised) 40 mcg eqv to vilanterol 25 mcg

Canada - English - Health Canada

glaxosmithkline inc - fluticasone furoate; umeclidinium (umeclidinium bromide); vilanterol (vilanterol trifenatate) - powder - 100mcg; 62.5mcg; 25mcg - fluticasone furoate 100mcg; umeclidinium (umeclidinium bromide) 62.5mcg; vilanterol (vilanterol trifenatate) 25mcg - antimuscarinics antispasmodics

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone furoate; umeclidinium as bromide; vilanterol as trifenatate - powder for inhalation pre-dispensed - vilanterol as trifenatate 22 mcg/inh; umeclidinium as bromide 55 mcg/inh; fluticasone furoate 92 mcg/inh - vilanterol, umeclidinium bromide and fluticasone furoate - asthmatrelegy ellipta 92/55/22 mcg is indicated for the maintenance treatment of asthma in patients aged 18 years and older.trelegy ellipta 92/55/22 mcg should be prescribed for patients who are not adequately controlled on maintenance asthma medication, such as an ics/laba.important limitations of use:trelegy ellipta 92/55/22 mcg is not indicated for the relief of acute asthma.copd (chronic obstructive pulmonary disease)trelegy ellipta 92/55/22 mcg is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of a long-acting β2-agonist and a long-acting muscarinic antagonist.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

glaxo saudi arabia ltd., saudi arabia - fluticasone furoate,umeclidinium bromide,vilanterol - inhalation powder, pre-dispensed - 100,62.5,25 µg,

Canada - English - Health Canada

glaxosmithkline inc - fluticasone furoate; umeclidinium (umeclidinium bromide); vilanterol (vilanterol trifenatate) - powder - 200mcg; 62.5mcg; 25mcg - fluticasone furoate 200mcg; umeclidinium (umeclidinium bromide) 62.5mcg; vilanterol (vilanterol trifenatate) 25mcg - antimuscarinics antispasmodics

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone furoate; umeclidinium as bromide; vilanterol as trifenatate - powder for inhalation pre-dispensed - vilanterol as trifenatate 22 mcg/inh; umeclidinium as bromide 55 mcg/inh; fluticasone furoate 184 mcg/inh - vilanterol, umeclidinium bromide and fluticasone furoate - asthmatrelegy ellipta 184/55/22 mcg is indicated for the maintenance treatment of asthma in patients aged 18 years and older. trelegy ellipta 184/55/22 mcg should be prescribed for patients who are not adequately controlled on maintenance asthma medication, such as an ics/laba.important limitations of usetrelegy ellipta 184/55/22 mcg is not indicated for the relief of acute asthma.trelegy ellipta 184/55/22 mcg is not indicated for patients with copd.